Full Press Release Details
TONIX PHARMACEUTICALS HOLDING CORP. 8-K
Tonix Pharmaceuticals Enrolls First Patient
in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19
Results from COV-LOGIC Study Expected
in First Half of 2021
NEW YORK, September 15, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals
Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first
patient was enrolled in the observational COV-LOGIC study (TNX-C001), a study of humoral (antibody) and cellular (T cell) immune
responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19. The research is part
of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix's
TNX-1800, which is a live replicating, attenuated virus vaccine designed to protect against COVID-19.
"This represents a significant milestone for the Company
as the data we plan to collect from recovered and asymptomatic COVID-19 volunteers in this study will help inform vaccine development
on how to safely provide the same immune responses that others got from recovering from actual SARS-CoV-2 infection," said
Seth Lederman, M.D., President and CEO of Tonix. "Our goal with TNX-1800 is to develop a vaccine that is well tolerated,
produces strong, long-lasting immunity, and can be rapidly and broadly deployed. The features of a protective immune response to
SARS-CoV-2 remain unknown. But since SARS-CoV-2 is a virus, we believe that T cell responses, in particular T Helper Type 1, or
TH1 responses, will play an important, if not dominant, role in protecting against serious illness from COVID-19."
About the COV-LOGIC Study (TNX-C001)
The COV-LOGIC study is an observational multi-cohort sample collection
study designed to collect the blood and nasopharyngeal (NP) swabs from individuals who have, and have not, been previously infected
with SARS-CoV-2, or who have been intimately exposed to persons confirmed to have been infected with SARS-CoV-2, in order to analyze
their antibody titers and T-cell responses to specific proteins of SARS-CoV-2 and to detect SARS-CoV-2 RNA which may be persistent
in the nasopharynx at the time of sampling. For those individuals in whom viral RNA is detected during initial sampling, repeat
blood and NP swab samples may be collected to examine temporal virus/immune response dynamics. In addition, blood will be collected
for DNA extraction and exome sequencing in order to assess whether host genetic factors might influence these humoral or cellular
responses or viral persistence (if identified).
TNX-1800 is a live modified horsepox virus vaccine for
percutaneous administration that is designed to express the Spike protein of the SARS-CoV-2 virus that causes COVID-19 and to
elicit a predominant T cell response. Horsepox and vaccinia are closely related orthopoxviruses that are believed to share a
common ancestor. Live replicating orthopoxviruses, like vaccinia or horsepox, can be engineered to express foreign genes and
have been explored as platforms for vaccine development because they possess; (1) large packaging capacity for exogenous DNA
inserts, (2) precise virus-specific control of exogenous gene insert expression, (3) lack of persistence or genomic
integration in the host, (4) strong immunogenicity as a vaccine, (5) ability to rapidly generate vector/insert constructs,
(6) readily manufacturable at scale, and (7) ability to provide direct antigen presentation. Relative to vaccinia, horsepox
has substantially decreased virulence in mice1. Horsepox-based vaccines are designed to be single dose,
vial-sparing vaccines, which can be manufactured on conventional cell culturing systems, with the potential for mass scale
1Noyce RS, et al. (2018) PLoS One. 13(1):e0188453
About Southern Research
Founded in 1941, Southern Research (SR) is an independent,
501(c)(3) nonprofit, scientific research organization with more than 400 scientists and engineers working across three divisions:
Drug Discovery, Drug Development, and Engineering. SR has supported the pharmaceutical, biotechnology, defense, aerospace, environmental,
and energy industries. SR works on behalf of the National Institutes of Health, the U.S. Department of Defense, the U.S. Department
of Energy, NASA and other major aerospace firms, utility companies, and other external academic, industry and government agencies.
SR pursues entrepreneurial and collaborative initiatives to develop and maintain a pipeline of intellectual property and innovative
technologies that positively impact real-world problems. SR has numerous ongoing drug discovery programs, which encompass 18 drug
candidates to combat various forms of cancer, amyotrophic lateral sclerosis (ALS), Alzheimer's, schizophrenia, opioid use
disorder, human immunodeficiency virus, diabetes, kidney disease, Parkinson's, tuberculosis, influenza, and others. SR's
strong history, which includes over 75 years of successful collaborations to solve complex problems, has led to the discovery of
seven FDA-approved cancer drugs-a number rivaling any other U.S. research institute. Furthermore, experts at SR are well-equipped
to assist with the challenging landscapes of drug design and development technologies and market viability. SR is headquartered
in Birmingham, Alabama with additional laboratories and offices in Frederick, Maryland.
Further information about SR can be found at https://southernresearch.org/
About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on
discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate
suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The
immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune
diseases. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.
Tonix's lead vaccine candidate, TNX-1800*, is a live replicating vaccine based on the horsepox viral vector platform to
protect against COVID-19, primarily by eliciting a T cell response. Tonix expects data from animal studies of TNX-1800 in the
fourth quarter of this year. TNX-801*, live horsepox virus vaccine for percutaneous administration, is in development to protect
against smallpox and monkeypox and serves as the vector platform on which TNX-1800 is based. Tonix is also developing TNX-2300*
and TNX-2600*, live replicating vaccine candidates for the prevention of COVID-19, but using bovine parainfluenza as the vector.
Tonix's lead CNS candidate, TNX-102 SL**, is in Phase 3 development for the management of fibromyalgia. The Company expects
results from an unblinded interim analysis in September 2020 and topline data in the fourth quarter of 2020. Tonix is also currently
enrolling patients in a second Phase 3 study for the management of fibromyalgia using TNX-102 SL, the results for which are expected
in the second half of 2021. TNX-102 SL is also in development for agitation in Alzheimer's disease and alcohol use disorder
(AUD). The agitation in Alzheimer's disease program is Phase 2 ready with FDA Fast Track designation, and the AUD program
is also Phase 2 ready. Tonix s programs for treating addiction conditions also include TNX-1300* (T172R/G173Q double-mutant
cocaine esterase 200 mg, i.v. solution), which is in Phase 2 development for the treatment of life-threatening cocaine intoxication
and has FDA Breakthrough Therapy designation. TNX-601 CR** (tianeptine oxalate controlled-release tablets) is another CNS program,
currently in Phase 1 development as a daytime treatment for depression while TNX-1900**, intranasal oxytocin, is in development
as a non-addictive treatment for migraine and cranio-facial pain. Tonix's preclinical pipeline includes TNX-1600** (triple
reuptake inhibitor), a new molecular entity being developed as a treatment for PTSD; TNX-1500* (anti-CD154), a monoclonal antibody
being developed to prevent and treat organ transplant rejection and autoimmune conditions; and TNX-1700* (rTFF2), a biologic being
developed to treat gastric and pancreatic cancers.
*TNX-1800, TNX-801, TNX-2300, TNX-2600, TNX-1300, TNX-1500 and
TNX-1700 are investigational new biologics and have not been approved for any indication.
**TNX-102 SL, TNX-601 CR, TNX-1600 and TNX-1900 are investigational
new drugs and have not been approved for any indication.
This press release and further information about Tonix can be found
Forward Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking
words such as "anticipate," "believe," "forecast," "estimate," "expect,"
and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results
could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA clearances
or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related
to the timing and progress of clinical development of our product candidates; need for additional financing; uncertainties of patent
protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts
and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant
risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to
update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K
for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (the "SEC") on March 24,
2020, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly
qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date
Jessica Morris (corporate)